THE nation's largest cancer genomics initiative PrOSPeCT (Precision Oncology Screening Platform Enabling Clinical Trials) has hit a major milestone, with over 5,000 Australians diagnosed with hard-to-treat cancers receiving free comprehensive genomic profiling of their disease.
Data shows 75% of these patients have actionable genetic biomarkers, offering potential for personalised medical treatments.
Over 750 clinicians nationwide are actively referring patients, regardless of location or age.
Referrals come from all parts of Australia, with 38% from rural areas.
Patients aged 16 to 91 are benefiting from profiling, covering various cancer types.
The process, from consent to treatment recommendations, takes five to eight weeks.
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Jun 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Jun 24
